Fortress Biotech Subsidiary Sells $205M PRV, Nets Over $100M
Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher for $205 million, with Fortress Biotech receiving over $100 million. The voucher, issued after ZYCUBO’s FDA approval in January 2026, yields tiered royalties plus up to $128 million in milestones and allocates 20% of proceeds to the NIH.
1. PRV Sale Terms
Cyprium closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million, delivering over $100 million to Fortress Biotech as majority owner and allocating 20% of sale proceeds to the Eunice Kennedy Shriver Institute of Child Health and Human Development.
2. ZYCUBO Approval and Royalties
The voucher was granted following FDA approval of ZYCUBO in January 2026. Under the Sentynl transaction, Cyprium retains eligibility for tiered royalties on net ZYCUBO sales and can earn up to $128 million in aggregate milestone payments.
3. Strategic Use of Proceeds
Fortress Biotech plans to deploy the funds to bolster business development and advance its diversified portfolio of commercial products and clinical-stage assets across oncology, dermatology and rare diseases, leveraging enhanced financial flexibility to drive future growth.